HERCULES, Calif. - Bio-Rad Laboratories (NYSE:BIO), Inc. (NYSE: BIO and BIO.B), a $8.49 billion market cap company known for its life science research and clinical diagnostics products, has announced ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter. The letter can be downloaded here. The fund returned -0.33% in the third ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt ...

Oct 26 (Reuters) - Bio-Rad Laboratories (BIO.N), opens new tab on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro ...

ddPCR reportedly provides quantification of target molecules with unprecedented precision and sensitivity. Bio-Rad Laboratories purchased QuantaLife for $162 million in cash plus future milestone ...

Bio-Rad Labs (BIO) has delivered a -5.60% change over the past year, with a 52-week range between 211.43 and 373.69. What Is the Average Daily Trading Volume of Bio-Rad Labs (BIO)? The average daily ...

Bio-Rad Laboratories (BIO) has expanded its collaboration with Biodesix, aiming to clinically validate and pursue regulatory approval for cancer biomarker diagnostic assays. The partnership highlights ...

BIO is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of BIO shares has increased $4.74 since the market last closed. This is a 1.49% ...

SAN FRANCISCO (CN) – Bio-Rad CEO Norman Schwartz testified Monday in a whistleblower retaliation trial that despite urging from his board of directors and other top executives, he was reluctant to ...